NEXTURNBIOSCIENCE Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Young-Hwa Jung

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders

Mar 28

Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return

Jan 25

CEO

Young-Hwa Jung (64 yo)

no data

Permanencia

Mr. Jung Young-Hwa serves as the Chief Executive Officer of NexturnBioscience Co., Ltd (formerly known as Nexturn Co.,Ltd.)

NEXTURNBIOSCIENCE Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders

Third quarter 2023 earnings released: EPS: ₩15.40 (vs ₩470 loss in 3Q 2022)

NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.

NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 5.9999959 billion in funding

NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 8.999999034 billion in funding from Flask Co., Ltd., GLK Equity Investment, SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.

NEXTURNBIOSCIENCE Co., Ltd. (KOSDAQ:A089140) agreed to acquire a 10.59% stake in Mirae Corporation (KOSE:A025560) from KANGLIM Co., Ltd (KOSDAQ:A014200).

First quarter 2023 earnings released: EPS: ₩37.00 (vs ₩48.00 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: ₩138 loss per share (vs ₩138 loss in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Less than half of directors are independent

NexturnBioscience Co., Ltd (KOSDAQ:A089140) acquired 8.83% stake in EV Advanced Material Co.,Ltd (KOSDAQ:A131400) from SL Vionics Co., Ltd. (KOSDAQ:A214310)

Studio Santa Claus Entertainment Co., Ltd. (KOSDAQ:A204630) acquired an additional 5.7% minority stake in NexturnBioscience Co., Ltd (KOSDAQ:A089140) from pacing, Sohn Young-sook, Peng Mi-sun and Shin Ji-yoon for KRW 9.8 billion.

Nexturn Bio Inc. Decides to Invest in the Development of A New Drug Pipeline for Diabetes Treatment Using Mirna

NexturnBioscience Co., Ltd announced that it has received KRW 13 billion in funding from Sangsangin Savings Bank, Investment Arm, Baro Savings Bank

NexturnBioscience Co., Ltd announced that it expects to receive KRW 13 billion in funding from Sangsangin Savings Bank, Investment Arm, Baro Savings Bank

New 90-day high: ₩17,550

New 90-day high: ₩13,900

Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return

New 90-day high: ₩13,700

New 90-day high: ₩12,100

New 90-day high: ₩10,000

New 90-day high: ₩8,780

New 90-day high - ₩8,610

New 90-day low - ₩7,140

CEO

Permanencia